Governor Stitt Was Right to Veto SB 2074. Now the Real Work Starts
Back in February, when Sen. Alvord filed Senate Bill 2074, I wrote here that the bill was a price floor wearing a due-process costume — a mandate that PBMs reimburse pharmacies at no less than NADAC plus a Medicaid-pegged dispensing fee, backed by a retroactive appeals regime with almost no cost ceiling. Despite that, the bill cleared the Senate in March and the House in April with comfortable margins. On April 22, Governor Stitt vetoed it, and he vetoed it for exactly the reasons this space raised in February.
What the Governor said
Stitt's veto message didn't mince words. Rewriting the reimbursement formula, he wrote, means "the state is further inserting itself into the marketplace to pick winners and losers." According to reporting from Oklahoma Business Voice, his office also characterized the bill's practical effect as a hidden tax that would ultimately land on families, employers, and small businesses through higher premiums — the exact cost-shifting mechanism I flagged when the bill was first filed: a mandated floor doesn't make the cost disappear, it just moves it from PBMs to whoever pays the health plan.
The numbers back that up. Oklahoma Business Voice reported that Stitt's office put the cost to the Oklahoma Health Care Authority alone at more than $11 million, and that the veto followed opposition letters from a genuinely broad slice of the state's employer and insurer base: ONG, ONEOK, American Fidelity, American Airlines, Koch Industries, Blue Cross Blue Shield of Oklahoma, Hobby Lobby, and both the State Chamber and the Greater Oklahoma City Chamber of Commerce. That's not a fringe coalition. That's most of the institutional employer base in the state saying the same thing: this bill costs real money, and it costs money that shows up in premiums, not in some abstract PBM ledger.
Credit where it's due
To his credit, Stitt didn't treat this as a simple "no." His veto message called the underlying goal — supporting rural and independent pharmacies squeezed by PBM reimbursement practices — commendable, while noting the bill didn't address the root issues and instead applied a one-size-fits-all rate mandate to a genuinely complex system. That's the right diagnosis. The pharmacies backing this bill have real grievances: MAC list opacity, slow appeals, reimbursements that lag actual acquisition costs. Those are transparency and process failures. SB 2074 tried to solve them by setting a price, and price floors set in statute don't flex when market conditions do — a point Stitt's message gestured at when it called for an approach that preserves market flexibility.
What comes next
KTEN's coverage of the veto framed this as a fight over who controls prescription payments and who ultimately pays the price. That's still the live question, and it isn't resolved by a veto — it's deferred. Rural pharmacy closures are a real problem in this state, and if the Legislature comes back with a narrower bill focused on MAC-list transparency, appeal-timeline enforcement, and audit standards — without a statutory price floor attached — that's a bill worth supporting. The mistake would be reintroducing SB 2074 largely unchanged next session and hoping for a different outcome. The employer coalition that helped sink this version isn't going anywhere, and neither is the $11 million question the Governor's office put on the table.
Sources
